

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/080356 A1

(51) International Patent Classification⁷: **C07D 257/04**,
401/14, 403/12, 401/12, 487/04, 403/06, A61K 31/41,
31/4439, 31/496, 31/497, A61P 25/00

(21) International Application Number:
PCT/US2005/005217

(22) International Filing Date: 17 February 2005 (17.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/545,291 18 February 2004 (18.02.2004) US

(71) Applicants (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE). **NPS PHARMACEUTICALS, INC.** [US/US]; 383 Colow Drive, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOHANSSON, Martin** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, S-151 85 Sofertälje (SE). **MINIDIS, Alexander** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **STAARF, Karin** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **WENSBO, David** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **MCLEOD, Donald** [US/US]; c/o NPS Pharmaceuticals, INC, 383 Colorow Drive, Salt Lake City, UT 84108 (US). **EDWARDS, Louise** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **ISAAC, Methvin** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway

Drive, Mississauga, Ontario L4V 1V7 (CA). **O'BRIEN, Anne** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Dr., Mississauga, Ontario L4V 1V7 (CA). **SLASSI, Abdelmalik** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Dr., Mississauga, Ontario L4V 1V7 (CA). **XIN, Tao** [CA/CA]; 10 Comoq Ave., Woodbridge, Ontario L4H 2B1 (CA).

(74) Agent: **DUFF, Meikle, Andrew**; Birch, Stewart, Kolasch & Birch, LLP, 8110 Gatehouse Road, Suite 500 East, P.O. Box 747, Falls Church, VA 22040-0747 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS



compounds, and to the use of said compounds in therapy.

(57) Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X¹, X², X³, X⁴, R¹, R², m and p, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said



WO 2005/080356 A1